Medscape
MANCHESTER, England — Febuxostat (Uloric) did not appear to increase the risk for major adverse cardiovascular (CV) events (MACEs) when compared with no urate-lowering therapy (ULT) in people with gout, according to findings from a real-world, retrospective cohort study reported at the British Society for Rheumatology (BSR) 2025 Annual Meeting…
Read More
Real-World Data Support Febuxostat’s Cardiovascular Safety
Leigha Schildgen
13:21
MANCHESTER, England — Febuxostat (Uloric) did not appear to increase the risk for major adverse cardiovascular (CV) events (MACEs) when compared with no urate-lowering therapy (ULT) in people with gout, according to findings from a real-world, retrospective cohort study reported at the British Society for Rheumatology (BSR) 2025 Annual Meeting…
